Hopp Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CureVac N V (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30%

Key Insights The considerable ownership by private equity firms in CureVac indicates that they collectively have a.

Gmbh coPublic company ownershipHopp biotechAsset management arm

Immatics N V (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 47% of the company

Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading.

New zealand generalNew zealandHarpreet singhGmbh coWellington management groupHopp biotechManagement groupNstitutional ownershipNdividual investorsHare registryNsider ownershipStock price

European Medicines Agency Accepts Novaliq s Marketing Authorization Application for CyclASol (ciclosporin ophthalmic solution) 0 1% for the Treatment of Dry Eye Disease

European Medicines Agency Accepts Novaliq s Marketing Authorization Application for CyclASol (ciclosporin ophthalmic solution) 0 1% for the Treatment of Dry Eye Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomBaden wübergUnited statesNovaliq gmbChristian roeskySimone angstmann mehrDrug administrationCommittee for medicinal products human useEuropean unionGmbh coNovaliq incHealth sciencesHarrow health incEuropean medicines agencyNovaliq gmbhMedicinal products

CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K -Today at 04:37 pm

CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income .

Noord hollandUnited statesOliver hoppDietmar hoppCurevacnv curevacAlexander zehnderMyriam mendilaAntony blancIgor splawskiCraig toomanDaniel hoppFranz werner haasDebra barkerFrame pharmaceuticalsCurevac groupGmbh co

Harrow Acquires U S and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0 1

VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four WeeksVEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) DosingNASHVILLE, Tenn. & HEIDELBERG, Germany (BUSINESS WIRE).

United statesBaden wübergUnited kingdomDeb hollidayPaul karpeckiLauram perimanMarkl baumNovaliq gmbJamie webbChristian roeskyUniversity of pikevillePeriman eye instituteSurface ophthalmics incPharmaceuticals incEye servicesGmbh co